Market News

Sivik Global Healthcare Raised Its Bio (BIO) Holding; Gates Capital Management Has Cut Eagle Materials (EXP) Stake By $9.26 Million

Bio-Rad Laboratories, Inc. (NYSE:BIO) Logo

Sivik Global Healthcare Llc increased Bio (BIO) stake by 25% reported in 2017Q4 SEC filing. Sivik Global Healthcare Llc acquired 2,500 shares as Bio (BIO)’s stock rose 2.21%. The Sivik Global Healthcare Llc holds 12,500 shares with $2.98 million value, up from 10,000 last quarter. Bio now has $7.80B valuation. The stock increased 0.30% or $0.79 during the last trading session, reaching $261.47. About 16,490 shares traded. Bio-Rad Laboratories, Inc. (NYSE:BIO) has risen 25.02% since April 23, 2017 and is uptrending. It has outperformed by 13.47% the S&P500.

Gates Capital Management Inc decreased Eagle Materials Inc (EXP) stake by 9.54% reported in 2017Q4 SEC filing. Gates Capital Management Inc sold 81,983 shares as Eagle Materials Inc (EXP)’s stock declined 6.85%. The Gates Capital Management Inc holds 777,657 shares with $88.11M value, down from 859,640 last quarter. Eagle Materials Inc now has $4.94 billion valuation. The stock increased 0.57% or $0.57 during the last trading session, reaching $101.45. About 91,842 shares traded. Eagle Materials Inc. (NYSE:EXP) has risen 5.94% since April 23, 2017 and is uptrending. It has underperformed by 5.61% the S&P500.

Among 5 analysts covering Bio-Rad Laboratories (NYSE:BIO), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Bio-Rad Laboratories had 20 analyst reports since August 7, 2015 according to SRatingsIntel. CL King downgraded the stock to “Neutral” rating in Friday, February 16 report. Wells Fargo maintained Bio-Rad Laboratories, Inc. (NYSE:BIO) on Wednesday, November 29 with “Buy” rating. CL King initiated the shares of BIO in report on Thursday, October 13 with “Buy” rating. The company was maintained on Thursday, June 8 by Jefferies. On Wednesday, September 27 the stock rating was maintained by Jefferies with “Buy”. The rating was maintained by Jefferies on Thursday, July 13 with “Buy”. C.L. King downgraded Bio-Rad Laboratories, Inc. (NYSE:BIO) on Friday, February 16 to “Hold” rating. The firm has “Buy” rating by Jefferies given on Wednesday, April 12. Jefferies maintained Bio-Rad Laboratories, Inc. (NYSE:BIO) rating on Friday, November 3. Jefferies has “Buy” rating and $300.0 target. The firm has “Buy” rating by Jefferies given on Friday, October 20.

Investors sentiment increased to 1.13 in 2017 Q4. Its up 0.35, from 0.78 in 2017Q3. It increased, as 23 investors sold BIO shares while 89 reduced holdings. 44 funds opened positions while 82 raised stakes. 18.57 million shares or 0.31% more from 18.51 million shares in 2017Q3 were reported. Earnest Partners holds 109,307 shares. Canada Pension Plan Board owns 9,400 shares or 0% of their US portfolio. Amp Investors Ltd has invested 0.02% in Bio-Rad Laboratories, Inc. (NYSE:BIO). Highland Cap Mgmt LP holds 4,400 shares or 0.05% of its portfolio. Ledyard Fincl Bank holds 0% of its portfolio in Bio-Rad Laboratories, Inc. (NYSE:BIO) for 114 shares. Thompson Siegel And Walmsley Ltd Liability reported 997 shares. Teacher Retirement System Of Texas has invested 0.01% in Bio-Rad Laboratories, Inc. (NYSE:BIO). Swiss Comml Bank has invested 0.01% in Bio-Rad Laboratories, Inc. (NYSE:BIO). 2,970 were accumulated by Btr Capital. State Of Alaska Department Of Revenue holds 3,800 shares or 0.02% of its portfolio. Texas Permanent School Fund reported 0.04% of its portfolio in Bio-Rad Laboratories, Inc. (NYSE:BIO). 8,569 are owned by Raymond James And Assocs. First Quadrant Lp Ca has 0% invested in Bio-Rad Laboratories, Inc. (NYSE:BIO) for 1,000 shares. Fmr Limited Liability Company has 0% invested in Bio-Rad Laboratories, Inc. (NYSE:BIO) for 144,095 shares. Intrepid Capital holds 0.31% in Bio-Rad Laboratories, Inc. (NYSE:BIO) or 3,409 shares.

Since December 14, 2017, it had 0 insider buys, and 1 sale for $1.24 million activity. Another trade for 4,980 shares valued at $1.24M was made by TSINGOS CHRISTINE A on Thursday, December 14.

Sivik Global Healthcare Llc decreased Baxter Intl Inc Com Stk (NYSE:BAX) stake by 20,000 shares to 100,000 valued at $6.46M in 2017Q4. It also reduced Wellcare Health Plans Inc Com Stk (NYSE:WCG) stake by 10,000 shares and now owns 35,000 shares. Stryker Corp Com (NYSE:SYK) was reduced too.

Investors sentiment increased to 1.13 in Q4 2017. Its up 0.08, from 1.05 in 2017Q3. It increased, as 23 investors sold EXP shares while 99 reduced holdings. 47 funds opened positions while 91 raised stakes. 45.84 million shares or 4.15% more from 44.01 million shares in 2017Q3 were reported. Aperio Grp Ltd invested in 12,797 shares. Qs Invsts Limited Liability Company has 0.03% invested in Eagle Materials Inc. (NYSE:EXP) for 30,636 shares. Dupont Management accumulated 43,800 shares or 0.11% of the stock. Geode Capital Mngmt Lc reported 388,293 shares stake. Fil owns 13,700 shares. Hm Payson And holds 0.01% of its portfolio in Eagle Materials Inc. (NYSE:EXP) for 2,164 shares. Ny State Common Retirement Fund stated it has 156,591 shares or 0.02% of all its holdings. Point72 Asset Lp reported 72,000 shares. Alpine Woods Capital Invsts Lc has invested 0.04% in Eagle Materials Inc. (NYSE:EXP). Moreover, Capital Fincl Advisers Ltd has 0% invested in Eagle Materials Inc. (NYSE:EXP). Landscape Mngmt Ltd Limited Liability Company holds 0.02% of its portfolio in Eagle Materials Inc. (NYSE:EXP) for 2,052 shares. Retirement Of Alabama invested in 0.03% or 62,874 shares. 2,390 are owned by Jane Street Grp Limited Liability Corp. Ascend Ltd Liability Co reported 0.04% of its portfolio in Eagle Materials Inc. (NYSE:EXP). 2,295 were reported by Coldstream Management.

Gates Capital Management Inc increased Altaba Inc stake by 450,000 shares to 2.45 million valued at $171.13M in 2017Q4. It also upped Welbilt Inc stake by 74,927 shares and now owns 3.53 million shares. Ishares Tr (Put) (IWM) was raised too.

Analysts await Eagle Materials Inc. (NYSE:EXP) to report earnings on May, 17. They expect $1.08 earnings per share, up 22.73% or $0.20 from last year’s $0.88 per share. EXP’s profit will be $52.56 million for 23.48 P/E if the $1.08 EPS becomes a reality. After $1.63 actual earnings per share reported by Eagle Materials Inc. for the previous quarter, Wall Street now forecasts -33.74% negative EPS growth.

Eagle Materials Inc. (NYSE:EXP) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *